Prof. Chakrabarty genetically engineered a new species of Pseudomonasbacteria in 1971 while working for the Research & Development Center at General Electric Company in Schenectady, New York. At the time, four known species of oil-metabolizing bacteria were known to exist, but when introduced into an oil spill, they competed with each other, limiting the amount of crude oil that they degraded. The genes necessary to degrade oil were carried on plasmids, which could be transferred among species. By irradiating the transformed organism with UV light after plasmid transfer, Prof. Chakrabarty discovered a method for genetic cross-linking that fixed all four plasmid genes in place and produced a new, stable, bacterial species capable of consuming oil one or two orders of magnitude faster than the previous four strains of oil-eating microbes. The new microbe, which Chakrabarty called "multiplasmid hydrocarbon-degrading Pseudomonas," could digest about two-thirds of the hydrocarbons that would be found in a typical oil spill. The bacteria drew international attention when he applied for a patent—the first U.S. patent for a genetically modified organism. He was initially denied the patent by the Patent Office because the patent code was thought to preclude patents on living organisms. The United States Court of Customs and Patent Appeals overturned the decision in Chakrabarty's favor, writing: Sidney A. Diamond, Commissioner of Patents and Trademarks, then appealed to the Supreme Court. The Supreme Court case was argued on 17 March 1980 and decided on 16 June 1980. This patent was granted by the U.S. Supreme Court, in a 5-4 decision, when it determined: Prof. Chakrabarty's landmark research has since paved the way for many patents on genetically modifiedmicro-organisms and other life forms, and catapulted him into the international spotlight.
Last work
His lab worked on elucidating the role of bacterial cupredoxins and cytochromes in cancer regression and arresting cell cycle progression. These proteins have been formerly known for their involvement in bacterial electron transport. He isolated a bacterial protein, azurin, with potential antineoplastic properties. He expanded his lab's work to include multiple microbiological species, including Neisseria, Plasmodia, and Acidithiobacillus ferrooxidans. In 2001, Prof. Chakrabarty founded a company, CDG Therapeutics, which holds proprietary information related to five patents generated by his work at the University of Illinois at Chicago. The University of Illinois owns the rights to the patents, but has issued exclusive licences to CDG Therapeutics. In 2008, Prof. Chakrabarty co-founded a second biopharmaceutical discovery company, Amrita Therapeutics Ltd., registered in Ahmedabad, Gujarat, to develop therapies, vaccines, and diagnostics effective against cancers and/or other major public health threats derived from bacterial products found in the human body. Amrita Therapeutics Ltd. received initial funding in late 2008 from Gujarat Venture Finance Limited, and later received a grant for a two-year research program in 2010 from the Indian Department of Biotechnology under the Biotechnology Industry Promotion Program.
